Preferences of patients and oncologists for the characteristics of the treatment for RCC in Spain and Portugal

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/29921
• EU PAS number:
  EUPAS29920
• Study ID:
  29921
• Official title and acronym:
  Preferences of patients and oncologists for the characteristics of the treatment for RCC in Spain and Portugal
• DARWIN EU® study:
  No
• Study countries:
  Portugal

  Spain
• Study description:
  This is an observational, multicentre, cross-sectional study of RCC (Renal Cell Carcinoma) patients and oncologists from Spain and Portugal. A DCE (Discrete Choice Experiment) will performed to elicit the preferences of RCC patients and oncologists.
• Study status:
  Planned

Research institutions and networks

Institutions

Hospital Santa Maria Nai

Universidad de Valladolid

Hospital Santa Maria Nai Ourense (Spain), Hospital Álvaro Cunqueiro Vigo (Spain), Hospital Universitario Donosti Donostia (Spain), Hospital Universitario Burgos Burgos (Spain), Hospital Universitario de Valladolid Valladolid (Spain), Hospital de Sagunto Sagunto (Spain), Complejo Hospitalario Universitario Insular Materno Infantil Las Palmas (Spain), Instituto Catalán de Oncología (ICO Badalona) Badalona Spain), Instituto Português de Oncologia Francisco Gentil Coimbra (Portugal), Hospital de Santo António dos Capuchos Lisboa (Portugal)

Study timelines

Date when funding contract was signed

Planned: 01/07/2019

Study start date

Planned: 01/07/2019

Data analysis start date

Planned: 01/11/2019

Date of final study report

Planned: 14/01/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bristol-Myers Squibb

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable